StockNews.AI
TLX
StockNews.AI
160 days

Telix Adds Lead-212 Isotope Production Capability

1. Telix develops breakthrough technology for lead-212 production. 2. New generators increase yield and shelf life significantly. 3. Production technology enables scalable alpha-emitting therapeutics. 4. Lead-212 offers potential for Targeted Alpha Therapy advancements. 5. Strategic deployment within distribution networks enhances commercial prospects.

9m saved
Insight
Article

FAQ

Why Bullish?

The development of the lead-212 generator presents significant commercial opportunities, comparable to past breakthroughs in pharmaceutical production (e.g., development of CAR-T therapies) that boosted stock prices significantly. The ability to enhance production capabilities while minimizing waste may lead to increased market competitiveness and revenue potential.

How important is it?

This development is crucial for TLX's future growth strategy, with potential long-term impacts on stock performance and its positioning in the oncology market as it addresses significant unmet medical needs.

Why Long Term?

The full financial impacts of the technology will emerge over time as TLX scales production and realizes market opportunities, similar to how Gilead's HIV advancements transformed its revenue streams over several years.

Related Companies

GILDBMYAVEO
March 12, 2025 18:41 ET  | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production. The new generator technology, developed internally by Telix’s IsoTherapeutics team, produces 212Pb via a sealed Thorium-228 (228Th) source, and significantly increases the amount of radioactivity, yield and shelf life compared to currently available 212Pb generators. The fully automated, high-output generators have a small, single hot cell footprint and produce sufficient 212Pb elution for up to 60 clinical doses, with the potential to further scale. The production footprint has been designed to be deployed throughout Telix’s (and select partner) manufacturing and distribution networks, including the recently acquired RLS Radiopharmacies network. This development builds on Telix’s extensive experience with developing generator-based radiopharmaceutical products. The novel technology opens new opportunities for the development of alpha-emitting radiopharmaceuticals for use in Telix’s next-generation therapeutics pipeline. Lead-212 is a promising isotope for Targeted Alpha Therapy (TAT) but its relatively short half-life (10.6 hours, compared with 9.9 days for actinium-225, 225Ac) and lack of production scale has limited commercial potential. The alpha-emitting profile of 212Pb also has practical synergies with engineered antibodies being developed using Telix’s newly acquired discovery platform1, with pharmacology and clearance organ characteristics that are well suited to its short half-life. Chad Watkins, General Manager, Isotope Strategy, Telix, said, “A lead-212 generator that produces minimal waste and fits within the current radiopharmacy footprint is a step change in the production of this alpha emitting therapeutic radioisotope. It creates the potential for commercial scale lead-212 isotope production that wasn't possible before and opens up new pathways for matching this promising alpha isotope with a range of targeting agents.” About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. ______________________________ 1 Telix ASX disclosure 31 January 2025. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

Related News